6533b7d3fe1ef96bd1261306

RESEARCH PRODUCT

Neutropenia tóxica tras ocrelizumab sin recurrencias posteriores tras continuar el tratamiento

F. Gascon-gimenezJ.a. Domínguez-moránA. Teruel-casasusJ.m. Láinez

subject

business.industryMedicineNeurology (clinical)businesshttps://doi.org/10.1016/j.neurop.2021.03.017